35530-07-5|Etiroxate, (S)-|ethyl (S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-2-methylpropanoate|-范德生物科技公司

Etiroxate, (S)-

NMR下载 COA and HPLC MSDS下载
names：
ethyl (S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-2-methylpropanoate
CAS号：
35530-07-5
MDL Number：
MF(分子式)： C18H17I4NO4 MW(分子量)： 818.95
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Etiroxate, (S)-
英文别名	Etiroxate, (S)-;
CAS号	35530-07-5
Inchi	InChI=1S/C18H17I4NO4/c1-3-26-17(25)18(2,23)8-9-4-13(21)16(14(22)5-9)27-10-6-11(19)15(24)12(20)7-10/h4-7,24H,3,8,23H2,1-2H3/t18-/m0/s1
InchiKey	LWZCMKGGFONJPB-SFHVURJKSA-N
分子式 Formula	C18H17I4NO4
分子量 Molecular Weight	818.95
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Etiroxate, (S)-(CAS:35530-07-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Etiroxate, (S)- has a lipid-lowering effect.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Schwartzkopff W, Hoffmann H, Nijssen J, Etzel V. [The effect of etiroxate on serum lipids after myocardial infarction or in angina pectoris]. Med Klin. 1976 Sep 17;71(38):1555-63. German. PubMed PMID: 185504.

[2]Weisweiler P, Schwandt P. Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients. Atherosclerosis. 1981 Apr;39(1):45-9. PubMed PMID: 7247989.

[3] Cervinková Z, Simek J, Trojovská V. Effect of triiodothyronine or etiroxate on DNA synthesis in intact and regenerating liver. Physiol Bohemoslov. 1984;33(6):501-6. PubMed PMID: 6241723.

[4] Schwartzkopff W, Russ E. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)]. MMW Munch Med Wochenschr. 1975 May 9;117(19):827-30. German. PubMed PMID: 805950.

[5] Dobiásová M, Vítek V, Kopecká J. Effect of etiroxate on LCAT activity and on certain energy metabolism enzymes in the rat. Physiol Bohemoslov. 1982;31(4):323-7. PubMed PMID: 6215662.

6: Knüchel F. [Clinical experience with etiroxate hydrochloride in patients with primary hyperlipoproteinemia]. Med Welt. 1977 Jan 28;28(4):186-9. German. PubMed PMID: 320426.7: Zadák Z, Kalinová M, Sobotka L. [Etiroxate treatment for hyperlipoproteinaemia type IIa and IIb (author's transl)]. Cas Lek Cesk. 1982 May 14;121(19):593-5. Czech. PubMed PMID: 7093991.8: Beckmann R. [Expeimental studies in animals on a new lipid lowering compound: etiroxate hydrochloride (author's transl)]. Arzneimittelforschung. 1979;29(3):499-508. German. PubMed PMID: 582735.9: Dobiásová M, Vondra K, Matousek V, Válek J. Rate of LCAT-mediated cholesterol esterification and serum lipids during etiroxate therapy in hyperlipoproteinemia. Atherosclerosis. 1982 Apr;42(2-3):251-61. PubMed PMID: 7073804.10: Banz H, Gall FP. [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison]. Fortschr Med. 1979 Nov 8;97(42):1942-1947. German. PubMed PMID: 520990.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开